Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant L19IL2/L19TNF plus surgery vs surgery in stage III B/C melanoma
2024-515749-40-00Phase 3Authorised
- Sponsor
- Philogen
- Start
- Jul 2024
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of darleukin and onfekafusp alfa in primary cutaneous melanoma (CM) (2 arms), sponsored by Philogen. Primary endpoint: Recurrence-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
primary cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2024-515749-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515749-40-00.